Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies
Muhammad Hammad , Sadaf Fardoos , Khadija Shakoor
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004162
Neurodegenerative and neurodevelopmental neurological disorders represent a growing global health burden, characterized by progressive neuronal dysfunction, cognitive decline, and impaired functional outcomes. Increasing evidence highlights neuroinflammation as a central pathophysiological mechanism linking mitochondrial dysfunction, oxidative stress, microbiota dysbiosis, and synaptic impairment across diverse neurological conditions. This narrative review was conducted using a structured literature search approach, incorporating major biomedical databases to enhance transparency and reproducibility. This review synthesizes contemporary evidence on mechanistic pathways underlying neuroinflammation-mediated neurodegeneration and critically evaluates emerging neuroprotective therapeutic strategies. Particular emphasis is placed on mitochondrial transfer approaches, novel circulating and imaging biomarkers, and integrative neurotechnological innovations such as artificial intelligence-driven neuroimaging analytics. While several therapeutic approaches demonstrate promise in preclinical models, most remain at early experimental or translational stages, with limited validation in large-scale human studies. Current findings suggest that targeting neuroimmune signaling cascades, restoring mitochondrial bioenergetics, and modulating gut-brain axis interactions may provide synergistic neuroprotective benefits. The review proposes a multidimensional precision-medicine framework incorporating biomarker-guided therapeutic selection and interdisciplinary care models. Future research priorities include longitudinal biomarker validation, randomized clinical trials of mitochondrial-based therapies, and integration of digital neurodiagnostic platforms to enhance early disease detection. Despite these advances, significant gaps remain in clinical translation, standardization of biomarkers, and long-term therapeutic safety, necessitating cautious interpretation of emerging evidence.
neuroinflammation / neuroprotection / biomarkers / mitochondrial therapy / neurodegeneration / gut-brain axis
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
Appel SH. Inflammation in Parkinson’s disease: cause or consequence? Mov Disord. 2012; 27: 1075-7. |
| [25] |
|
| [26] |
|
| [27] |
Graeber MB. Neuroinflammation: no rose by any other name. Brain Pathol. 2014; 24: 620-2. |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014; 20: 5507-9. |
| [49] |
|
| [50] |
|
| [51] |
Neurology TL. Bringing forward the diagnosis of Alzheimer’s disease. Lancet Neurol. 2014; 13: 961. |
| [52] |
|
| [53] |
|
| [54] |
Daponte A, Koros C, Skarlis C, Siozios D, Rentzos M, Papageorgiou SG, |
| [55] |
Galizzi G, Carlo MD. Mitochondrial DNA and Inflammation in Alzheimer’s Disease. Curr Issues Mol Biol. 2023; 45: 8586-606. |
| [56] |
Shayota BJ. Biomarkers of mitochondrial disorders. Neurotherapeutics. 2024; 21: e00325. |
| [57] |
|
| [58] |
Schöll M. Advances in Alzheimer’s Disease. Brain Connect. 2023; 13: 266-8. |
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
Peruzzo D, Castellani U, Perlini C, Bellani M, Marinelli V, Rambaldelli G, |
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
Mirzaei G, Gupta A, |
| [89] |
Miyata K. Editorial: Role of assistive technologies to offer diagnosis, intervention and rehabilitation for individuals with neurological or neurodevelopmental disorder. Front Psychiatry. 2023; 14: 1159267. |
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
Fang S, Yin Z, Cai Q, Li L, Zheng P, |
| [101] |
|
| [102] |
|
| [103] |
Liu L, Feigin V, Sacco RL, |
/
| 〈 |
|
〉 |